SLC5A2 and chronic kidney disease: The EMPA-KIDNEY trial assessed the effects of empagliflozin in 6609 patients with CKD, including approximately two-thirds of participants with an investigator-reported non-diabetic primary kidney disease.2,6 Effects among patients with different primary causes of CKD are important to consider, as different pathophysiology might be expected to respond differently to SGLT2 inhibition.